Browse > Article

Inhibitory Effects of the Roots of Cudrania tricuspidata Bureau on Osteoclast Differentiation  

Kim, Yu-Gyeong (College of Pharmacy, Keimyung University)
Jeong, Gil-Saeng (College of Pharmacy, Keimyung University)
Publication Information
Korean Journal of Pharmacognosy / v.48, no.2, 2017 , pp. 155-159 More about this Journal
Abstract
Cudrania tricuspidata Bureau (Moraceae) is a traditional oriental medicine that has been widely used as anti-oxidant, anti-inflammatory and immunomodulatory in Korea. This study was performed that the 70% ethanol extract of the roots of C. tricuspidata (CTE) suppressed receptor activator of NF-${\kappa}B$ ligand (RANKL)-induced osteoclastogenesis, actin ring formation in RAW 264.7 cell lines. CTE significantly inhibited the JNK/mitogen-activated protein kinase (MAPK) signaling pathway without affecting ERK and p38 signaling in RANKL-stimulated RAW 264.7 cells. Also, CTE inhibited RANKL-induced expression of c-Fos, an upstream activator of NFATc1. Consequently, CTE suppresses osteoclast differentiation by inhibiting RANKL induced MAPK signaling pathways and disrupts the actin rings in mature osteoclasts. Thus, CTE can be used for the development of osteoporosis treatment drug with a natural material.
Keywords
Cudrania tricuspidata Bureau; Osteoclastogenesis; RANKL; MAPK; c-Fos; NFATc1;
Citations & Related Records
Times Cited By KSCI : 3  (Citation Analysis)
연도 인용수 순위
1 Nie, S. B., Xu, J. W., Zhang, C. H., Xu, C., Liu, M. and Yu, D. G. (2015) Salicortin inhibits osteoclast differentiation and bone resorption by down-reuglating JNK and NF-${\kappa}B$/ NFATc1 signaling pathways. Biochem. Biophys. Res. Commun. 470: 61-67.
2 Wu, Y. B., Zheng, C. J., Qin, J. P., Sun, L. N., Han, T., Jiao, L., Zhang, Q. Y. and Wu, J. Z. (2009) Antiosteoporotic activity of anthraquinones from Morinda officinalis on osteoblasts and osteoclasts. Molecules 1: 573-583.
3 Murakiami, H., Takahashi, N., Tanaka, S., Nakamura, I., Udagawa, N., Nakajo, S., Nakaya, K., Abe, M., Yuda, Y., Konno, F., Barbier, A. and Suda, T. (1997) Tiludronate inhibits protein tyrosine phosphatase activity in osteoclasts. Bone 20: 399-404.   DOI
4 Hadjdaksis, D. J. and Androulakis, I. I. (2006) Bone remodeling. Ann. N. Y. Acad. Sci. 1092: 385-396.   DOI
5 Li, C. H., Yang, Z. F., Li, Z. X., Ma, Y., Zhang, L. P. Zheng, C. B., Qiu, W. W., Wu, X. A., Wang, X., Li, H., Tang, J., Qian, M., Li, D., Wang, P., Luo, J. A. and Liu, M. G. (2011) Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-${\kappa}B$ and MAPK signaling pathways. J. Bone Miner. Res. 26: 644-656.   DOI
6 Lee, J. H., Jin, H. X., Shim, H. E., Kim, H. N., Ha, H. I. and Lee, Z. H. (2010) Epigallocatechin-3-gallate inhibits osteoclastogenesis by down-regulating c-Fos expression and suppressing the nuclear factor-${\kappa}B$ signal. E. Mol. Pharmacol. 77: 17-25.   DOI
7 Teitelbaum, S. L. (2007) Osteoclasts: What do they do how do they do it? Am. J. Pathol. 170: 427-435.   DOI
8 Lee, H. J., Do, J. R., Kwon, J. H. and Kim, H. Y. (2011) Physiological activities of extracts from different parts of Cudrania tricuspidata. J. Korean Soc. Food Sci. Nutr. 40: 942-948.   DOI
9 Choi, S. R., You, D. H., Kim, J. Y., Park, C. B., Kim, D. Y. and Ryu, J. (2009) Antioxidant activity of methanol extracts from Cudrania tricuspidata Bureau according to harvesting parts and time. Korean J. Medicianl Crop. Sci. 17: 115-120.
10 Kim, O. K., Ho, J. N., Nam, D. E., Jun, W. J., Hwang, K. T., Kang, J. E., Chae, O. S. and Lee, J. M. (2012) Hepatoprotective effect of Cudrania tricuspidata extracts against oxidative damage. J. Korean Soc. Food Sci. Nutr. 41: 7-13.   DOI
11 Kwon, J. Y., Hiep, N., Kim, D. W., Hong, S. G., Guo, Y., Hwang, B. Y., Lee, H. J., Mar, W. C. and Lee, D. H. (2016) Chemical constituents isolated from the root bark of Cudrania tricuspidata and their potential neuroprotective effects. J. Nat. Prod. 79: 1938-1951.   DOI
12 Geng, X. L., Yang, L. B., Zhang, C., Qin, H. and Liang, Q, D. (2015) Wogonin inhibits osteoclast differentiation by inhibiting NFATc1 translocation into the nucleus. Exp. Ther. Med. 10: 1066-1070.   DOI
13 Goltzman, D. (2002) Discoveries, drugs and skeletal disorders. Nat. Rev. Drug. Discov. 1: 784-796.   DOI